| Study Period | 2021 - 2032 |
| Market Size in 2025 | USD 37.0 Billion |
| Market Size in 2026 | USD 39.5 Billion |
| Market Size by 2032 | USD 61.6 Billion |
| Projected CAGR | 7.6% |
| Largest Region | North America |
| Fastest-Growing Region | Asia-Pacific |
| Market Structure | Consolidated |
Explore the market potential with our data-driven report
The plasma fractionation market size was USD 37.0 billion for 2025, and it will grow by 7.6% during 2026–2032, to reach USD 61.6 billion by 2032.
This growth is supported by the expanding utilization of immunoglobulins, albumins, and coagulation factors across neurology, immunology, and hematology for treating immune deficiencies, bleeding disorders, and chronic neurological conditions. Globally, immunoglobulins account for more than half of total plasma-derived product demand, driven by chronic indications requiring lifelong therapy and high per-patient annual dosing volumes, particularly in neurology and primary immunodeficiency treatment. The increasing prevalence of rare diseases requiring lifelong plasma therapy, combined with technological advances in ion-exchange chromatography and affinity chromatography techniques, is reinforcing market expansion.
The demand for plasma fractionation is further strengthened by growing plasma collection infrastructure worldwide and expanding regulatory approvals for plasma-derived therapeutics. According to the Pan American Health Organization, 23 countries in Latin America and the Caribbean collected 9,212,861 units of blood in 2023, a 15.5 % increase compared to 7,776,198 units in 2020. Nearly 57 % of donated blood in the region was from voluntary, non‑remunerated donors in 2023, marking a return to pre‑pandemic growth trends. A significant proportion of plasma is collected for fractionation purposes to support the production of plasma-derived medicinal products.
The plasma fractionation industry is undergoing substantial technological evolution through adoption of advanced ion-exchange chromatography and affinity chromatography systems that increase protein yield, reduce processing time, and improve product purity compared to traditional ethanol precipitation methods. Modern chromatography columns enable selective binding and elution of specific plasma proteins including immunoglobulins, albumin, and coagulation factors, achieving separation resolutions that historical Cohn fractionation processes could not deliver.
These improvements translate directly into manufacturing economics by extracting greater therapeutic protein quantities from each liter of source plasma processed, effectively expanding supply without proportional increases in plasma collection infrastructure. Advanced chromatography-based fractionation processes have been shown to increase recoverable immunoglobulin yield per liter of plasma by 20–30% compared to legacy ethanol precipitation methods, improving supply efficiency without proportional expansion of plasma collection networks.
The shift toward chromatography-based fractionation is further reinforced by regulatory expectations from authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), which emphasize validated, reproducible purification processes under Good Manufacturing Practice (GMP) requirements to ensure batch consistency, impurity control, and product safety.
Process automation and continuous manufacturing approaches are replacing batch production systems, reducing labor requirements while minimizing contamination risks and improving consistency across production runs. Viral inactivation technologies have advanced substantially, incorporating solvent-detergent treatment, pasteurization, and nanofiltration steps that eliminate pathogen risks while preserving protein biological activity.
These viral safety steps are mandatory under the regulatory frameworks of the FDA, EMA, and WHO for plasma-derived medicinal products. This makes advanced purification technologies essential for regulatory compliance, rather than optional process enhancements. These safety enhancements enable regulatory approvals in markets with stringent quality requirements, expanding addressable market reach for manufacturers investing in state-of-the-art facilities.
Moreover, structural constraints in plasma availability and regulatory tightening continue to influence market dynamics. Regional blood donation shortfalls in parts of Latin America and Sub-Saharan Africa, where donation rates remain significantly below global averages, limit the availability of plasma suitable for fractionation and reinforce global supply imbalances. Additionally, evolving regulatory initiatives, such as the Substances of Human Origin (SoHO) Regulation in Europe, are expected to further harmonize quality and safety standards while potentially increasing compliance costs, particularly for smaller fractionators and national blood services.
The global demographic shift toward older populations represents a fundamental driver accelerating demand for plasma-derived therapies across immunoglobulin, albumin, and coagulation factor categories. The WHO projects that the population aged 60 years and older will increase from 1.1 billion in 2023 to 1.4 billion by 2030, representing a 27% expansion within seven years that concentrates disease burden among cohorts requiring long-term therapeutic management.
Clinical research indicates that more than 90% of adults over age 65 present with at least one chronic disease, while approximately 60% manage two or more concurrent conditions requiring sustained medical intervention. This multimorbidity pattern creates compounding demand for immunoglobulin treatments addressing immune dysfunction, albumin infusions supporting liver disease and shock management, and coagulation factors preventing bleeding complications during surgical procedures that become more frequent with advancing age.
The causal mechanism operates through biological aging processes that compromise immune system function, reduce hepatic protein synthesis, and alter coagulation cascades, creating clinical dependencies on exogenous plasma proteins that healthy younger populations do not require. Healthcare systems in high-income markets with mature insurance frameworks provide reimbursement coverage for these expensive therapies, translating epidemiological disease burden directly into commercial demand.
The immunoglobins category holds the largest market share, of 55%, in 2025, owing to the wider commercial availability of plasma-derived immunoglobulins compared to other products and their increasing usage, especially for treating patients with chronic inflammatory demyelinating polyneuropathy or intrinsic immune deficits. Moreover, the rising prevalence of neurological and immunological diseases and increasing off-label indications for IVIg.
Additionally, the usage of SCIg is growing due to its ease and reduced time of administration. The FDA has approved SCIg for maintenance therapy in adult patients with CIDP. This has expanded treatment options beyond traditional IVIG administration and enabling home-based therapy that improves patient independence and reduces healthcare facility burden. Immunoglobulins are also used to fight the effect of immune dysfunctions that occur with age-related changes. The category further benefits from extensive reimbursement coverage across developed markets, supporting high annual treatment costs that can exceed USD 100,000 per patient. Thus, with the growing prevalence of infectious diseases, the use of immunoglobulins is expected to increase in the future.
Coagulation factors have the highest CAGR, of 7.7%, driven by greater diagnosis and treatment of bleeding disorders such as hemophilia and von Willebrand disease, alongside expanding surgical procedures and trauma care needs. Globally, over 210,000 people with hemophilia now receive factor replacement therapy, up from around 190,000 in 2018, highlighting broader clinical adoption.
The proportion of patients on prophylactic treatment has increased from 39 % in 2010 to 57 % in 2023, reflecting improved access and awareness. National programs in countries like India and Brazil report that the number of patients treated with recombinant factor VIII has more than doubled over the last decade, while WHO and WFH data show that over 80 % of patients in high-income countries receive routine factor replacement, further supporting the global growth trend.
The product types analyzed in this report are:
The ion-exchange chromatography category holds the largest market share, of 50%, in 2025, due to the usage of this technology for plasma fractionation has resulted in the creation of a new generation of therapeutic plasma derivatives, particularly coagulation factors, protease inhibitors, and anticoagulants. The implementation of chromatography techniques has also allowed for the development of new products with improved purity and safety for treating congenital or acquired plasma protein deficiencies.
This technology dominates through proven scalability that enables processing of millions of liters annually within single manufacturing facilities, regulatory familiarity where decades of FDA and EMA approvals validate ion-exchange processes for commercial plasma fractionation, and cost-effectiveness achieved through reusable column matrices and straightforward buffer systems requiring minimal specialized equipment. Single large-scale fractionation facilities utilizing ion-exchange chromatography are capable of processing over 10 million liters of plasma annually, supporting economies of scale and consistent global product supply.
The affinity chromatography category will have the highest CAGR, of 7.8%, supported by superior purification specificity that enables single-step isolation of target proteins through biological recognition mechanisms, reduced processing time compared to multi-step ion-exchange protocols, and higher final product purity meeting increasingly stringent regulatory quality standards. This technology achieves selectivity through immobilized ligands that bind specific plasma proteins with high affinity, enabling direct capture from crude plasma fractions without extensive pre-purification steps. Protein A affinity chromatography for immunoglobulin purification and heparin affinity columns for coagulation factor isolation exemplify applications delivering 95%+ purity in single chromatographic passes.
The technologies analyzed in this report are:
The neurology category holds the largest market share, in 2025, driven by established immunoglobulin therapy protocols for chronic inflammatory demyelinating polyneuropathy, Guillain-Barré syndrome, multifocal motor neuropathy, and myasthenia gravis. These neurological conditions require long-term or lifelong immunoglobulin maintenance therapy, creating recurring revenue streams as patients receive monthly infusions preventing disease relapse and preserving motor function. CIDP alone generates substantial market demand with patients requiring 1–2 grams per kilogram bodyweight monthly, translating to 60–80 grams per infusion for average adults and annual consumption exceeding 700 grams per patient.
The oncology category will have the highest CAGR, reflecting albumin utilization in chemotherapy formulations, immunoglobulin applications for cancer-related immunodeficiency, and emerging adoptions addressing immune checkpoint inhibitor toxicities. The International Agency for Research on Cancer (IARC) reports that there are an estimated 20 million new cancer cases and 9.5 million cancer deaths globally each year. Projections further indicate that the cancer burden will increase approximately 77% by 2050, to reach 35 million annual cases.
The applications analyzed in this report are:
The hospitals & clinics category holds the largest market share, of 70%, in 2025, reflecting their role as primary administration sites for intravenous plasma therapies requiring healthcare professional supervision, access to infusion infrastructure, and immediate medical intervention capacity for managing infusion reactions. Hospital dominance stems from intravenous immunoglobulin protocols mandating clinical observation during and following administration. This is due to potential systemic adverse events, including anaphylaxis, hemolysis, and thrombotic complications, which require emergency response capabilities unavailable in outpatient settings. Major teaching hospitals and specialized treatment centers serve as high-volume plasma therapy providers, with individual facilities administering thousands of immunoglobulin infusions annually across neurology, hematology, and immunology departments.
The laboratories category will have the highest CAGR, driven by expanding research applications, clinical trial requirements, and diagnostic testing utilizing plasma-derived reference materials. Academic research laboratories increasingly employ purified plasma proteins as reagents for basic science investigations exploring immune system function, coagulation mechanisms, and protein structure-function relationships. Contract research organizations supporting biopharmaceutical development require authenticated plasma standards for analytical method validation and product characterization studies. Clinical laboratories performing specialized coagulation testing or immunology assays utilize plasma-derived controls and calibrators ensuring measurement accuracy across different testing platforms.
The end users analyzed in this report are:
Drive strategic growth with comprehensive market analysis
North America holds the largest market share, of 45%, in 2025, due to the ongoing development in the pharmaceutical R&D sector, growing population of hemophilic patients, rising number of plasma collection centers, booming paid plasma donation activities, and expanding product portfolios and geographical presence of the top market players in North America.
Moreover, the increased awareness of the advantages of plasma and a rise in the cases of respiratory disorders make region profitable for plasma fractionation market players, sustained by its extensive plasma collection network exceeding 800 donation centers across the region. The United States operates the world's most-comprehensive paid plasma donation system, enabling significantly higher per capita plasma collection volumes compared to voluntary donation models prevalent in other regions. Federal regulatory frameworks established by the U.S. Food and Drug Administration provide clear pathways for plasma product approvals, with multiple immunoglobulin and coagulation factor therapies receiving marketing authorization annually.
The region's market position is further reinforced by robust healthcare expenditure exceeding USD 4 trillion annually, comprehensive insurance coverage facilitating patient access to expensive plasma therapies, and strong research infrastructure supporting clinical trials for novel plasma-derived products. The trajectory remains positive through 2032, supported by aging demographics increasing demand for immunoglobulins in neurology applications, expanding indications for coagulation factors in surgical settings, and continued investment in advanced fractionation technologies that improve yield efficiency and reduce manufacturing costs.
The United States accounted for the largest share within North America in 2025, driven by its position as the primary global source of source plasma and the concentration of major fractionation facilities. The U.S. has over 600 licensed plasma donation centers operated by integrated plasma companies, with donor compensation models enabling twice-weekly donations. This generates significantly higher plasma volumes per capita compared to international voluntary systems. Federal support for plasma medicine development through FDA Fast Track and Breakthrough Therapy designations accelerates time-to-market for innovative therapies addressing unmet medical needs in immunology and hematology.
Clinical demand continues expanding across multiple therapeutic areas, with immunoglobulins experiencing particularly strong growth for treating chronic inflammatory demyelinating polyneuropathy, primary immunodeficiency disorders, and neurological conditions. The market trajectory through 2032 remains robust, supported by ongoing facility expansions by Grifols in Clayton, North Carolina (12 million liters annual fractionation capacity) and new product launches addressing specialized patient populations requiring low-IgA formulations or extended dosing intervals.
Asia-Pacific will have the highest CAGR, of 7.9%, driven by rapidly expanding healthcare infrastructure in China and India, increasing diagnostic capabilities identifying patients with previously unrecognized immunodeficiency and bleeding disorders, and substantial government investments in domestic plasma fractionation capacity to reduce reliance on imported therapies. China has implemented national policies prioritizing plasma self-sufficiency, with major fractionation facilities operated by Shanghai RAAS Blood Products Co. Ltd., China Biologic Products Holdings Inc., and Hualan Bioengineering Co. Ltd. collectively processing millions of liters annually. However, China's regulatory environment prohibits plasma imports except albumin, creating a closed domestic market that protects local manufacturers.
Japan represents a mature market with sophisticated healthcare systems, accelerated regulatory pathways through the Pharmaceuticals and Medical Devices Agency for extended half-life coagulation factors, and high per capita consumption of immunoglobulin products driven by aging demographics. South Korea is experiencing particularly rapid market expansion, supported by GC Pharma's domestic manufacturing capabilities and government initiatives encouraging plasma donation to support local therapeutic production. India's market development is accelerating through facility investments by Intas Pharmaceuticals Ltd. and regulatory reforms facilitating plasma collection, though infrastructure constraints and limited cold chain logistics in rural areas continue restricting patient access.
The trajectory through 2032 remains highly positive, with Indonesia planning its first fractionation plant with 600,000-liter annual capacity through public–private partnerships. Additionally, Thailand is expanding plasma collection networks to support domestic demand, and Australia maintains strong production through CSL Limited's manufacturing operations.
The regions and countries of the market are as follows:
The market exhibits a consolidated competitive structure, with three multinational companies—CSL Limited, Takeda Pharmaceutical Company Limited, and Grifols S.A.—holding a major collective share This high concentration results from substantial structural barriers including capital intensity exceeding USD 500 million for greenfield fractionation facilities, regulatory complexity requiring years to achieve manufacturing approvals across multiple jurisdictions, vertically integrated business models that necessitate ownership of hundreds of plasma collection centers to secure raw material supply, and extensive manufacturing expertise accumulated over decades of plasma protein purification experience.
The consolidated structure creates significant competitive moats for established players, while limiting new entrant threats, as demonstrated by the absence of meaningful new fractionator market entry in developed regions over the past two decades despite attractive market growth rates and strong therapeutic demand fundamentals. The market's consolidated structure, substantial capital requirements, and regulatory complexities are likely to preserve the current competitive hierarchy while enabling leading players to maintain pricing discipline and achieve attractive returns on their substantial infrastructure investments.
Want a report tailored exactly to your business need?
Request CustomizationLeading companies across industries trust us to deliver data-driven insights and innovative solutions for their most critical decisions. From data-driven strategies to actionable insights, we empower the decision-makers who shape industries and define the future. From Fortune 500 companies to innovative startups, we are proud to partner with organisations that drive progress in their industries.
Working with P&S Intelligence and their team was an absolute pleasure – their awareness of timelines and commitment to value greatly contributed to our project's success. Eagerly anticipating future collaborations.
McKinsey & Company
India
Our insights into the minutest levels of the markets, including the latest trends and competitive landscape, give you all the answers you need to take your business to new heights
We take a cautious approach to protecting your personal and confidential information. Trust is the strongest bond that connects us and our clients, and trust we build by complying with all international and domestic data protection and privacy laws
Customize the Report to Align with Your Business Objectives
Request the Free Sample Pages